|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
1996-7-15
|
|
pubmed:abstractText |
We evaluated the role of ABMT in late 1st CR AML adult patients using busulfan plus cyclophosphamide as preparative regimen. Fifty-one adult patients (mean age 36 years, range 15-59) with AML underwent ABMT in 1st CR. Three of them had a prior diagnosis of myelodysplastic syndrome; one patient had a secondary leukemia. The median interval between CR and ABMT was 8 months (range 4-20). Patients received busulfan, 4 mg/kg/day for 4 days plus cyclophosphamide 50 mg/kg/day for 4 days or 60 mg/kg/day for 2 days. No maintenance chemotherapy was administered after ABMT. Median days to reach 0.5 x 10(9)/I PMN and 20 x 10(9)/I platelets were 26 (range 12-250) and 74 (range 16-740), respectively. No transplant-related deaths were observed. Five-year actuarial overall survival rate is 76.9%; actuarial leukemia-free survival rate is 70.6%. Mean follow-up from ABMT is 35 months. Leukemia-free survival of this group was compared with that of 38 non-transplanted patients younger than 60 years, who maintained a CR longer than 8 months in the same period. This analysis shows a statistically significant difference in favor of ABMT patients. These results suggest that, even if performed late after 1st CR as post-remission intensification, ABMT can improve the outcome of AML patients.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0887-6924
|
|
pubmed:author |
pubmed-author:BandiniGG,
pubmed-author:BelardinelliAA,
pubmed-author:FiacchiniMM,
pubmed-author:GerominAA,
pubmed-author:GherlinzoniFF,
pubmed-author:ManfroiSS,
pubmed-author:MangiantiSS,
pubmed-author:MiggianoM CMC,
pubmed-author:MottaM RMR,
pubmed-author:RicciPP,
pubmed-author:RizziSS,
pubmed-author:RostiGG,
pubmed-author:TestoniNN,
pubmed-author:TuraSS,
pubmed-author:VisaniGG
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
10
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
402-9
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:8642854-Adolescent,
pubmed-meshheading:8642854-Adult,
pubmed-meshheading:8642854-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:8642854-Bone Marrow Transplantation,
pubmed-meshheading:8642854-Busulfan,
pubmed-meshheading:8642854-Combined Modality Therapy,
pubmed-meshheading:8642854-Cyclophosphamide,
pubmed-meshheading:8642854-Cytarabine,
pubmed-meshheading:8642854-Daunorubicin,
pubmed-meshheading:8642854-Disease-Free Survival,
pubmed-meshheading:8642854-Etoposide,
pubmed-meshheading:8642854-Female,
pubmed-meshheading:8642854-Follow-Up Studies,
pubmed-meshheading:8642854-Humans,
pubmed-meshheading:8642854-Idarubicin,
pubmed-meshheading:8642854-Leukemia, Myeloid, Acute,
pubmed-meshheading:8642854-Logistic Models,
pubmed-meshheading:8642854-Male,
pubmed-meshheading:8642854-Middle Aged,
pubmed-meshheading:8642854-Prognosis,
pubmed-meshheading:8642854-Proportional Hazards Models,
pubmed-meshheading:8642854-Remission Induction,
pubmed-meshheading:8642854-Survival Rate,
pubmed-meshheading:8642854-Time Factors,
pubmed-meshheading:8642854-Transplantation, Autologous
|
|
pubmed:year |
1996
|
|
pubmed:articleTitle |
Autologous bone marrow transplantation in late first complete remission improves outcome in acute myelogenous leukemia.
|
|
pubmed:affiliation |
Istituto di Ematologia Seràgnolí, Università di Udine, Italy.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't
|
